The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Expression analysis of MET, EGFR, and HER2, and K-ras mutation status in patients with stage II/III gastric cancer enrolled in the ACTS-GC study.
Atsushi Ochiai
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Koji Kitada
Research Funding - Taiho Pharmaceutical
Wataru Ichikawa
Honoraria - Taiho Pharmaceutical
Masanori Terashima
Honoraria - Taiho Pharmaceutical
Issei Kurahashi
Consultant or Advisory Role - Taiho Pharmaceutical
Hitoshi Katai
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Ryoji Kushima
Research Funding - Taiho Pharmaceutical
Mitsuru Sasako
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical